Ownership and insider activity for Genelux Corporation (GNLX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Price
| Price | $2.34 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $425000 | $11.3M | $4.5M | $397000 | $9.4M | $8.6M | $5.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | $13.8M | $22.3M | $9.3M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $551000 | $11.5M | $5.8M | $1.9M | $24.2M | $31.5M | $15.1M |
| Property, Plant & Equipment | $2.6M | $2.5M | $2.2M | $2.0M | $3.6M | $3.1M | $3.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $3.3M | $14.0M | $8.1M | $5.5M | $27.9M | $34.7M | $19.0M |
| Accounts Payable | 0 | $927000 | $4.5M | $6.8M | $3.8M | $5.6M | $4.4M |
| Short-term Debt | $4.6M | $3.6M | $6.2M | $16.4M | 0 | $329000 | 0 |
| Total Current Liabilities | $14.7M | $14.5M | $22.5M | $31.6M | $6.6M | $6.9M | $6.2M |
| Long-term Debt | $13.0M | $21.7M | $18.0M | $8.5M | 0 | 0 | 0 |
| Total Liabilities | $28.1M | $36.7M | $41.2M | $41.3M | $8.4M | $8.4M | $7.5M |
| Retained Earnings | -$154.6M | -$168.2M | -$184.6M | -$189.8M | -$221.5M | -$251.4M | -$283.5M |
| Total Equity | -$24.8M | -$22.7M | -$33.1M | -$35.8M | $19.5M | $26.3M | $11.5M |
| Total Debt | $18.0M | $26.1M | $25.3M | $26.4M | $2.5M | $1.9M | $1.7M |
| Net Debt | $17.5M | $14.7M | $20.8M | $26.0M | -$20.7M | -$29.0M | -$12.9M |
| Working Capital | -$14.2M | -$3.0M | -$16.7M | -$29.7M | $17.6M | $24.6M | $8.9M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 2.39 |
Profitability
| Return on Equity | -195.42% |
| Return on Invested Capital | -192.18% |
| Return on Assets | -128.96% |
| Gross Margin | -1762.50% |
| Operating Margin | -445200.00% |
| Net Margin | -422412.50% |
Related companies: ACIU · ALDX · CADL · CLLS · CTNM · DRTS · LXEO
Explore sector: Healthcare · Biotechnology
More sections of GNLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks